30.9 C
Vientiane
Tuesday, September 16, 2025
spot_img
Home Blog Page 23

SPTel and iWOW Technology Partner to Expand Wireless Alert Alarm System Initiative across Singapore

SINGAPORE, Sept. 15, 2025 /PRNewswire/ — SPTel and iWOW Technology (iWOW) today announced their partnership to support the expansion of the wireless Alert Alarm System (AAS) initiative, extending emergency assistance to seniors in public rental flats across Singapore. This deployment marks the first use of SPTel’s island-wide LoRaWAN network to facilitate emergency assistance, and builds on iWOW’s successful wireless AAS pilot in 2019.

The wireless AAS allows seniors to receive timely assistance during emergencies through alert buttons in their homes that connect to a 24/7 emergency hotline. To ensure reliable and resilient connectivity, SPTel will provide its island wide LoRaWAN-powered sensor network, multi-network SIM solution and IoT-as-a-Service (IoT-a-a-S) platform, while iWOW will provide the alert buttons.

“Our sensor network infrastructure, IoT platform and Multi-Network SIM solutions are designed to enable IoT applications to scale securely, rapidly and cost-effectively. We are pleased to partner iWOW on this project, contributing our network coverage and IoT solutions to this meaningful initiative to enhance support for our seniors. We look forward to supporting more initiatives that drive meaningful impact for our communities,” said Titus Yong, CEO of SPTel. 

“We are excited to partner with SPTel to expand the reach of our proven age-tech solutions like the AAS initiative and our alert button to more seniors across Singapore. With Singapore set to become a super-aged society by 2026, the urgency to ensure seniors can age safely and independently at home has never been greater,” said Jer Yaw Chen, Senior VP of iWOW Technology.

SPTel will be providing its suite of IoT infrastructure solutions to support the deployment, including:

  • Island-wide sensor network powered by LoRaWAN that enables large scale deployment of the wireless alert devices, with long-range data transmission and low power consumption that support battery life, allowing IoT devices to operate for up to five years without the need for replacement. A more efficient and cost-effective option for low-data transmission use cases compared to 4G, 5G and WiFi, the LoRaWAN gateways are also solar-powered, supporting more sustainable digitalisation for businesses in Singapore. This makes it an ideal solution for the AAS deployment as well as other IoT applications such as tree tilt monitoring, environmental monitoring and rodent monitoring systems. 
  • IoT-a-a-S platform is a multi-protocol, application-agnostic platform that connects and integrates the wireless alert devices for consolidated management. Delivering end-to-end services such as data processing and application hosting, the subscription-based platform removes the need for upfront infrastructure investment, accelerating deployment. It also lays the groundwork for future integration of other sensors and IoT devices across various smart city applications.
  • Multi-network SIM supporting the LoRaWAN sensor network ensures vital, uninterrupted connectivity during emergencies by connecting the sensor network to all three major mobile networks in Singapore. In the event of a disruption on the primary mobile network, it automatically switches to the next available network, enhancing network resilience.

The wireless AAS deployment is currently underway and will be completed by 2030.

About SPTel

SPTel uses unique fibre pathways that combine leased SP Group infrastructure and owned fibre pipes, laid alongside the power network cables. As a leading provider of next-generation telecommunications and digital solutions SPTel places a strong focus on innovation and reliability. This enables SPTel to deliver secure and scalable connectivity, edge cloud, IoT-a-a-S and managed security solutions to businesses, government agencies, and service providers. SPTel is committed to driving digital transformation by providing cutting-edge technologies and exceptional customer experiences.

For more information, please visit www.sptel.com.

About iWOW Technology

iWOW (SGX: NXR), which stands for Inspiring the World of Wireless, is a Singapore-listed technology company specialising in integrated wireless IoT solutions offered as a service. Guided by a vision to enable a smarter, greener, and safer world, iWOW develops innovative IoT solutions that address the evolving needs of an increasingly urbanised, ageing and resource-constrained world. Specifically, its age-tech offerings are delivered through its dedicated subsidiary, BOP Pte Ltd.

For more information on iWOW, please visit www.iwow.com.sg

Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations

SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 /PRNewswire/ — Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval represents the third major regulatory milestone for the same product candidate, which previously received both Fast Track and Orphan Drug Designations for the treatment of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC).

The IND clearance authorizes Lion TCR to commence clinical studies of LioCyx-M004 in CHB patients – a global population exceeding 290 million – and marks the first TCR-T therapy to enter clinical development for chronic hepatitis B.

“This triple recognition from the FDA underscores the transformative potential of LioCyx-M004 and validates our strategic approach targeting HBV-associated diseases through TCR-T cell therapy,” said Dr. Xiaoming Peng, CEO of Lion TCR. “Having demonstrated promising anti-tumor and antiviral activity in liver cancer, we are now well-positioned to evaluate its impact on the underlying viral infection that drives cancer development.”

The company’s earlier regulatory achievements include Orphan Drug designation, which provides incentives for therapies targeting rare diseases such as HBV-HCC in the United States, and Fast Track status, designed to accelerate the development and review of treatments for serious conditions addressing unmet medical needs.

LioCyx-M004 represents an innovative autologous cell therapy engineered using mRNA to encode T-cell receptors that specifically target hepatitis B virus antigens. Preclinical and early clinical studies have demonstrated the therapy’s ability to reduce viral antigen load and promote T-cell-mediated clearance of infected cells, while maintaining a favorable safety profile to date.

Dr. Tina Wang, Chief Medical Officer of Lion TCR, added, “Our ability to successfully redirect our lead candidate from oncology to virology demonstrates the remarkable versatility and broad therapeutic potential of our platform. We look forward to initiating the CHB trial and exploring its potential as a functional cure for this chronic infection.”

The company’s mRNA-encoded in vivo TCR-T therapy targeting HBV has gained validation from a prominent U.S. cancer research institute. Studies have demonstrated significant efficacy in eliminating HBV-positive cells in animal models, with therapeutic effects comparable to ex vivo engineered T cells. This validation provides a robust scientific foundation for the industrialization of in vivo TCR-T therapy targeting HBV.

Lion TCR is actively advancing this innovative approach, accelerating the development of in vivo TCR-T therapy. Compared to traditional ex vivo T cell therapies, the in vivo platform offers distinct advantages including shorter production cycles, reduced costs, and enhanced accessibility, potentially expanding treatment opportunities for patients worldwide.

Additionally, the company is enhancing its AI-powered TCR discovery platform with plans to expand its product pipeline to address additional solid tumor indications, including lung cancer, breast cancer, and gastrointestinal cancers.

About Lion TCR

Lion TCR is a clinical-stage biotechnology company that originated from the Agency for Science, Technology and Research (A*STAR) in Singapore. The company’s lead product targets hepatitis B virus (HBV)-related diseases and represents the world’s first HBV-specific TCR-T cell therapy to receive U.S. FDA approval for an international multi-center Phase II clinical trial. It has been granted FDA Fast Track designation and Orphan Drug status, in addition to obtaining approval for clinical trials from China’s National Medical Products Administration (NMPA).

Utilizing an AI-powered TCR discovery platform and advanced RNA technology, Lion TCR is expanding its pipeline to address various solid tumors as well as infectious diseases. The company’s diversified portfolio includes both autologous cell therapies and off-the-shelf treatments, with a dedicated focus on developing in vivo TCR-T therapies aimed at significantly reducing costs and improving treatment accessibility.

Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101

SHANGHAI and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ — Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company’s lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology.

“This is a critical milestone for Phrontline as we advance our mission to deliver innovative ADC therapies that can meaningfully impact patients’ lives,” said Zhaoyuan “Tony” Chen, Chief Executive Officer of Phrontline Biopharma. “The initiation of this study not only represents the progress of our lead candidate, TJ101, but also demonstrates the strength of our platform and the dedication of our team in advancing breakthrough science into the clinic. Running this trial in both China and the United States reflects our commitment to a truly global clinical development strategy and ensures early alignment with international regulatory standards.”

The Phase 1 study of TJ101 will evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity across multiple solid tumor types. The study design includes dose escalation followed by expansion cohorts to further assess TJ101’s potential in a broad patient population.

“This first patient dosing is a major step forward in validating our ADC platform,” said Martín Sebastian Olivo, MD, Chief Medical Officer of Phrontline Therapeutics. “Our team has worked tirelessly to design a program that explores the full clinical potential of TJ101 while also laying the groundwork for our broader pipeline of differentiated ADCs. Beyond TJ101, we are advancing a portfolio of next-generation bispecific dual payload ADCs, which aim to overcome resistance mechanisms seen with current therapies and broaden the scope of patients who may benefit.”

Phrontline’s pipeline includes multiple early-stage ADC assets targeting high-value tumor antigens. The company’s dual payload platform leverages a modular design with optimized linker stability and distinct mechanisms of action, enabling improved tumor penetration and a stronger bystander effect.

“By combining scientific innovation with a clear clinical strategy, we are building a robust ADC pipeline that we believe can transform the standard of care in oncology,” added Dr. Chen.

About Phrontline Biopharma
Phrontline Biopharma is a biotechnology company headquartered in Suzhou, China, focused on developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of solid tumors. Leveraging proprietary linker-drug technology and a differentiated dual payload approach, Phrontline aims to deliver more effective and durable treatment options for patients with high unmet medical needs.

EverBridge Group and Cosmotec Forge Landmark Partnership

SHANGHAI, Sept. 15, 2025 /PRNewswire/ — EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market.

Jay Wang (Left) and Suguru Ominato (Right)
Jay Wang (Left) and Suguru Ominato (Right)

This strategic collaboration underscores EverBridge Group’s leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence.

Simultaneously, the partnership underscores Cosmotec’s best-in-class digital commercialization platform, which accelerates market access for international medical devices and enables targeted engagement with clinical end-users.

“EverBridge Group’s portfolio demonstrates outstanding clinical efficiency and user-friendly design, aligning perfectly with Japanese physicians’ pursuit of advanced therapeutic solutions,” stated Suguru Ominato, CEO of Cosmotec. “By integrating M3’s academic platforms with our localized commercialization expertise, we will accelerate the adoption of these devices across the Japanese market.”

“Cosmotec’s digital commercialization model delivers both efficiency and accessibility, which aligns perfectly with our vision for equitable healthcare innovation,” said Jay Wang, CEO of EverBridge Group. “By navigating Japan’s rigorous technical and regulatory landscape, this partnership not only delivers transformative solutions to patients but also enhances our global R&D synergy. Lowering barriers to advanced care through innovation and ecosystem collaboration remains central to our globalization journey.”

About EverBridge Group

EverBridge Group is a leading medical technology group in Asia, committed to providing global customers with cutting-edge, high-quality, and affordable medical technologies. Our rapidly expanding product portfolio covers three major therapeutic areas: peripheral vascular, neuroscience, and oncology. Supported by Six specialized R&D and lean production centers, we offer top-tier OEM/ODM services in areas including balloons, catheters, stents, surface engineering, and active medical devices.

We collaborate extensively with outstanding enterprises worldwide, building a bridge for medical technology innovation between Asia and the rest of the world. Our goal is to offer healthcare professionals and patients globally better treatment options through advanced and accessible solutions.

For more information, please visit the official website: www.everbridgemed.com

Contact: Ann Chencommunications@everbridgemed.com

Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium

  • 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025).
  • The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® clinical value was highlighted across three key dimensions, consistent with the new disease management strategy of “Treat the cause, Treat early, Treat long-term.” 
  • NEFECON® is currently the only etiological treatment for IgAN recommended by both domestic and international guidelines, reinforcing its position as the foundational first-line cornerstone treatment for IgAN patients.

SHANGHAI, Sept. 15, 2025 /PRNewswire/ — At the 18th International lgA Nephropathy Symposium (IIgANN 2025), 7 new abstracts based on real-world evidence of NEFECON® will be presented. The 18th IIgANN will take place in Prague, Czech Republic, from September 17 to 20, 2025.

The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). The clinical value of NEFECON® was highlighted across three key dimensions, consistent with the new disease management strategy of “Treat the cause, Treat early, Treat long-term.” In real-world clinical practice, there is strong validation of NEFECON®‘s value as an etiological treatment, where early intervention is critical in reducing proteinuria and protecting renal function, and extended treatment beyond 9 months provided robust evidence supporting sustained efficacy and safety.

These real-world evidence not only address the limitations of randomized controlled trials (RCTs) in clinical practice but also reinforce the new disease management strategy of “Treat the cause, Treat early, Treat long-term”. They further strengthen NEFECON®‘s position as the world’s first etiological treatment for IgAN, providing strong scientific evidence to advance both clinical practice and global research.

NEFECON® has been recommended by several authoritative treatment guidelines, including the “KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)”, and the “Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)”. NEFECON® was included in China’s National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON® has been officially approved by NMPA in August 2025.

NEFECON® is currently the world’s first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency(MHRA)in the United Kingdom, as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea.

Abstracts

1.   Abstract Number: P-45
Title: Beyond Nine Months: Real-World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy
Principal author and institution: Chiwa Aoieong, Xiu Yang. Kiang Wu Hospital, Department of Nephrology, Macao, China; Hangzhou First People’s Hospital Affiliated to Westlake University School of Medicine, Department of Nephrology, Hangzhou, China
Abstract:The study is to assess the efficacy and safety of 12-month Nefecon therapy in IgAN patients in a real-world setting, compared to conventional treatment. In conclusion, twelve-month Nefecon therapy significantly reduced proteinuria and preserved renal function in IgAN patients, with a better safety profile compared to conventional treatment involving systemic corticosteroids and immunosuppressants.

2.   Abstract Number: P-44
Title: Efficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study
Principal author and institution: Shasha Chen, Guisen Li, Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital, Department of Nephrology, Chengdu, China.
Abstract: The study is to evaluate the clinical efficacy and safety of Nefecon (budesonide enteric capsules) in patients with IgA nephropathy (IgAN). In conclusion, Nefecon significantly reduces proteinuria and improves renal function in IgAN patients, with a favorable safety profile. These findings support its potential as a first-line therapeutic option for IgAN. Further randomized controlled trials with larger cohorts are warranted to validate these results.

3.    Abstract Number: P-43
Title: Budesonide enteric capsules* for IgA nephropathy with hepatitis B virus infection: Two cases
Principal author and institution: Shasha Chen, Guisen Li, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital,Department of Nephrology, Chengdu, China
Abstract: The study is to evaluate the efficacy and safety of budesonide enteric capsules in patients with IgAN and chronic HBV infection. In conclusion, budesonide enteric capsules combined with intensive supportive therapy effectively improved renal outcomes in IgAN patients with HBV coinfection without triggering viral reactivation. This case report provides an evidence-based support for the use of budesonide enteric capsules in the special population, suggesting that targeted intestinal immunity modulate the number and activity of mucosal B cells in ileal Peyer’s patches may be a preferred strategy under strict HBV biomarker monitoring.

* Budesonide enteric capsules are Nefecon.

4.   Abstract Number: P-63
Title: First real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis 
Principal author and institution: Yu Zhang, Jianhua Zhou, Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Abstract: The study is to evaluate the efficacy of Nefecon in pediatric patients with IgAN/IgAVN. In conclusion, in this real-world setting, Nefecon shows a significant impact on reducing proteinuria and hematuria in pediatric patients with IgAN/IgAVN. However, its potential inhibition of the hypothalamic-pituitary-adrenal axis remains a concern that warrants meticulous consideration by pediatric nephrologists.

5.   Abstract Number: P-64
Title: Efficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study
Principal author and institution: Junjun Zhang, Zhanzheng Zhao, The Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Abstract: The study is to assess real-world clinical outcomes and safety of Nefecon in Chinese IgAN patients. This real-world analysis demonstrates Nefecon’s sustained renoprotective effects in Chinese IgAN patients, particularly those with preserved renal function (eGFR ≥35 mL/min/1.73m²), with progressive proteinuria reduction and hematuria resolution. The favorable safety profile supports its clinical utility in this population.

6.   Abstract Number: P-48
Title: Nefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6 – Month Observational Study
Principal author and institution: Ming Fang,Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Renal Translational Medicine Center of Liaoning Province, Dalian, China
Abstract: The study is to investigate the effectiveness and safety of Nefecon in patients with IgAN and renal insufficiency. In conclusion, six-month Nefecon therapy demonstrated potential stabilization of kidney function alongside modest proteinuria reduction, with favorable tolerability in high-risk IgAN populations.

7.   Abstract Number: P-62
Title: Early Intervention with Budesonide Enteric-Coated Capsules* in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function
Principal author and institution: Xiaoyan Xiao, Qilu Hospital of Shandong University, Department of Nephrology, Jinan, Shandong, China
Abstract: The study is to evaluate its efficacy and safety in the early treatment of IgAN. In conclusion, budesonide enteric-coated capsules significantly reduced proteinuria and stabilized renal function and well tolerated in the early treatment of IgAN. Early diagnosis and treatment of patients are particularly important in IgAN.

* Budesonide enteric capsules are Nefecon.

About NEFECON®

NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.

In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong SAR, Macao SAR, Taiwan, China and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine’s territories.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

30 Years of BODY WORLDS – A Success Story That Has Changed the Way We See Ourselves


HEIDELBERG, GERMANY – Newsaktuell – 15 September 2025 – Exactly 30 years ago today, on September 15, 1995, a new chapter in the history of exhibitions was opened in Tokyo — one that remains unparalleled worldwide: the premiere of the first BODY WORLDS exhibition at the Tokyo National Science Museum, held on the occasion of the 100th Annual Meeting of the Japanese Anatomical Society.

Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany
Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany

What no one could have foreseen at the time: this opening marked the beginning of an extraordinary success story. BODY WORLDS made the invisible visible — for the first time, millions of visitors gained fascinating insights into the human body in a way that had never been possible before.

Since then, more than 57 million people in over 170 cities and 42 countries across six continents have experienced the exhibitions. BODY WORLDS is now considered one of the most successful and influential exhibition concepts in the world.

The foundation for this success was laid by Dr. Gunther von Hagens with the invention of Plastination. What was once reserved for medical professionals became accessible and understandable to all through his technique.

Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany
Gunther von Hagens privat copyright: Institute for Plastination, Heidelberg/Germany

“From the very beginning, my goal was to democratize anatomy. I wanted to give people the opportunity to look inside themselves – not to break taboos, but as an invitation to gain knowledge of, respect, and responsibility for their own bodies,” explains von Hagens.

“BODY WORLDS has fundamentally changed the way we understand the human body and has contributed to a new culture of education about health and life,” adds Dr. Angelina Whalley, the exhibition’s curator, who has shaped the conceptual design from the start.

Even three decades after its debut, BODY WORLDS has lost none of its relevance – thanks to its universal subject: the human being. In an age of rapid change, digital overstimulation, and constant motion, the exhibition offers a rare moment of pause and reflection. Even the harsh criticism at the beginning — which emerged solely in Germany — has not changed this. Today, BODY WORLDS provides direct access to one’s own body, promotes health awareness, and encourages people to take responsibility for their lives.

It is precisely this combination of scientific education, personal relevance, and emotional impact that makes the exhibition timeless — and meaningful to every new generation.

30 Years of BODY WORLDS — a celebration of life that moves, inspires, and transforms people.

Discover our jubilee film on https://bit.ly/BW_AnniversaryFilm

– Picture is available at AP

The issuer is solely responsible for the content of this announcement.

Virtual IT Group and The Instillery Go to Town on Zero Trust

SHELLHARBOUR, Australia , Sept. 15, 2025 /PRNewswire/ — On the eve of Zscaler‘s Annual Australasian Zenith Live conference, Virtual IT Group is excited to announce the formation of a specialist Zero Trust practice. This initiative is enabled by its recent integration with New Zealand-based MSP The Instillery

The announcement follows on the heels of the trans-Tasman merger between Virtual IT Group and The Instillery which has already positioned the combined entity as one of the largest managed services and security providers operating in the region.  

“One of the key reasons we were attracted to The Instillery was their depth of capability in Zero Trust and their partnership with Zscaler,” said Virtual IT Group Founder and CEO Christian Pacheco

Pacheco added, “Our intention is to take a Zero Trust capability to market immediately by leveraging the Zscaler partnership and adding to our team internally. There is a massive unmet need in this space—among customers still relying on legacy security architectures, as well as those not realising the full value of their current Zero Trust investments.”

Eric Swift, Vice President & Managing Director, Zscaler Australia and New Zealand, said, “The collaboration between Virtual IT Group and The Instillery signals a pivotal moment for Zero Trust adoption across Australia and New Zealand.”

Swift added, “With cyber threats becoming increasingly sophisticated and legacy architectures struggling to keep pace, the combined expertise of these MSPs, alongside Zscaler Zero Trust ExchangeTM platform, will empower organisations to confidently modernise their security ecosystems and safeguard critical data without compromise.”

Instillery Group COO Jeremy Nees is driving the new Zero Trust practice across Australian and New Zealand with key new hires to be announced in the coming weeks. 

ENDS

About Virtual IT Group

Virtual IT Group is one of the fastest growing and capable MSP & MSSP providers in Australia and New Zealand. With scale, reach, and proven expertise, we deliver end-to-end managed services for infrastructure as well as security, cloud transformation, and modern workplace solutions that keep organisations productive, resilient, and secure – real cyber solutions for real cyber threats. 

www.vitg.com.au

IVD Medical Holding Limited Releases “ETHK” Ecosystem Vision: Technology for the Public, Chain for the Way On September 14


NEW YORK, US – Media OutReach Newswire – 14 September 2025 – IVD Medical Holding Limited (01931.HK) officially announced its name change. Its English name was changed to “ETHK Labs Inc.”. This move marks a comprehensive strategic upgrade, shifting the company’s focus to core technology research and development and output for the digital industry and on-chain financial ecosystem. Through this name change, IVD Medical Holding Limited aims to more accurately reflect its new position as a key technology provider for the “ETHK” on-chain financial ecosystem and further enhance the group’s competitiveness and influence in the global digital asset ecosystem.

Hashtag: #IVDMedical

The issuer is solely responsible for the content of this announcement.